MicroRNA Signature Predicted Breast Cancer Survival, Bone Metastasis
This video highlights a novel scoring system using microRNA signatures that predicted poor overall survival and bone metastasis in patients with luminal A breast cancer.
In this video, Kazuaki Takabe, MD, PhD, of Roswell Park Cancer Institute in Buffalo, New York, discusses a study that found that a scoring system using microRNA signatures predicted poor overall survival and bone metastasis in patients with luminal A breast cancer.
The researchers examined 1,051 patients from The Cancer Genome Atlas and discovered that microRNA signatures miR-19a, miR-93, and miR-106a were predictive for these outcomes. The results were validated in two separate cohorts.
Takabe presented the findings at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
